metastatic castration-resistant prostate cancer (mCRPC)
AstraZeneca Canada Inc.
NOC Status at Filing:
100 mg and 150 mg
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
As monotherapy for the treatment of adult patients with mCRPC and deleterious or suspected deleterious germline and/or somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.